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ABSTRACT Despite significant progress in reaching some milestones of the United
Nations Sustainable Development Goals, neonatal and early infant morbidity and mor-
tality remain high, and maternal health remains suboptimal in many countries. Novel
and improved preventative strategies with the potential to benefit pregnant women
and their infants are needed, with maternal and neonatal immunization representing
effective approaches. Experts from immunology, vaccinology, infectious diseases, clini-
cians, industry, public health, and vaccine-related social sciences convened at the 5th
International Neonatal and Maternal Immunization Symposium (INMIS) in Vancouver,
Canada, from 15 to 17 September 2019. We critically evaluated the lessons learned
from recent clinical studies, presented cutting-edge scientific progress in maternal and
neonatal immunology and vaccine development, and discussed maternal and neonatal
immunization in the broader context of infectious disease epidemiology and public
health. Focusing on practical aspects of research and implementation, we also dis-
cussed the safety, awareness, and perception of maternal immunization as an existing
strategy to address the need to improve maternal and neonatal health worldwide.
The symposium provided a comprehensive scientific and practical primer as well as an
update for all those with an interest in maternal and neonatal infection, immunity,
and vaccination. The summary presented here provides an update of the current sta-
tus of progress in maternal and neonatal immunization.
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Maternal and pediatric morbidity and mortality remain at the forefront of the inter-national public health agenda. Vaccines are safe and highly effective at reducing
death and disability in young children, but most vaccines are given weeks to months
after birth, while the highest pediatric mortality occurs around the time of birth and,
specifically, within the neonatal period (the first 28 days) (1). Neonatal mortality now
contributes nearly 50% to the overall global mortality of children under the age of
5 years, and novel or improved interventions are needed if this figure is to change.
Vaccines, given either to the infant at birth to induce active immunity or to mothers
during pregnancy to maximize the transfer of passive immunity via protective antibody
(Ab) across the placenta or into breast milk, can play a key role in this context or pro-
vide other protective immune functions (1). The safest and most effective strategies for
neonatal and maternal immunization need to be continuously reviewed. There is also
a need for a better understanding of how to ensure that existing vaccines can reach
vulnerable populations and to address the hesitancy about vaccine use, particularly
during pregnancy. This is particularly relevant as we face an ongoing threat with the
new coronavirus disease 2019 (COVID-19) pandemic. Many stakeholders, including
researchers, policymakers, research funders, nongovernmental organizations, vaccine
manufacturers, and frontline immunization providers, have to be involved to guaran-
tee optimal and rapid translation of research findings and implementation of the best
preventive strategies.
The 5th International Neonatal and Maternal Immunization Symposium (INMIS) con-
vened experts from immunology, infectious diseases, vaccinology, clinicians, industry,
public health experts, and social scientists in Vancouver, Canada, from 15 to 17
September 2019 to review the most relevant advances in maternal and neonatal im-
munization. The overarching focus of the conference was to review how best to secure
protection for the next generation (i.e., from mother to infant) against potentially pre-
ventable infectious diseases via maternal and early-life immunization strategies. Over
250 participants attended the 2.5-day meeting that included 11 invited expert presen-
tations, 28 oral presentations from submitted abstracts, 101 poster presentations, and
3 expert panel discussions. The meeting sessions were organized to begin with an
opening overview keynote address. On the first day, there were sessions on the themes
“Protecting newborns and infants through maternal immunization” and a “Multi-disci-
plinary approach to improve maternal vaccine uptake,” including a panel discussion,
“Overcoming hurdles to increase maternal vaccination uptake.” The second day was
dedicated to the themes “The mechanistic underpinnings of maternal and neonatal im-
munization” and “Promoting healthy infant life through optimizing neonatal immuni-
zation,” with the former including a panel and audience discussion, “How does the
maternal-newborn immune dyad communicate?” Finally, the third day focused on the
theme “The next generation of neonatal and maternal immunization research” with an
audience discussion of “Is the field on the right path? What are we missing?” The clos-
ing keynote speech addressed the controversial issue of the ethics of maternal immu-
nization research and implementation. A brief summary of the keynote presentations
follows, with subsequent sections each dedicated to one of the themes of the sympo-
sium. In light of the current COVID-19 pandemic, the current state of knowledge on
the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the
maternal-infant dyad is briefly discussed to consider the output of the meeting in the
perspective of the ongoing pandemic and given implications for SARS-CoV-2 vaccine
development and the inclusion of special populations, such as pregnant women.
Shabir A. Madhi (University of Witwatersrand, South Africa) highlighted that despite
global progress in reducing under-5-year-old childhood deaths as part of the Millennium
Development Goals agenda (1990 to 2015), reductions in mortality rates during the neo-
natal period lagged behind those for children 1 to 59months of age. Furthermore, there
has been limited focus on the prevention of stillbirths, despite the stillbirth rate exceed-
ing neonatal mortality rate in many low- and middle-income countries (LMICs). United
Nations Sustainable Development Goal (SDG) 3.2 aspires to prevent all preventable
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deaths of newborns and children by 2030, as well as to reduce neonatal mortality to 12
per 1,000 live births. In addition, the Every Newborn Action Plan aims to reduce stillbirth
rates from 20 to 10 per 1,000 births by 2035.
Dr. Madhi emphasized that quantifying the potential of maternal vaccines, or other
prophylactic interventions, in reducing maternal morbidity, stillbirth rates, and early-
infancy deaths requires in-depth and objective assessment of the causes of newborn
and infant deaths. Recent surveillance using minimally invasive tissue sampling has
unmasked the hitherto largely neglected contribution of infection as the dominant im-
mediate cause of stillbirth and neonatal deaths, including deaths usually attributed to
premature birth. This approach also has the potential to identify the potential contri-
bution of pathogens for which there are no current vaccines, for example, group B
Streptococcus (GBS) and Gram-negative bacteria. Such data are essential to inform the
prioritization of research and interventions aimed at reducing maternal and childhood
deaths.
The potential of maternal immunization (coupled with other possible changes) in
reducing neonatal mortality is manifest by the near elimination of neonatal tetanus
globally following the recommendation of routine tetanus vaccine immunization of
pregnant women (2). Furthermore, since the 2009 H1N1 influenza pandemic, there has
been an acceleration of research on the potential impact of maternal immunization in
improving maternal and child health, including the demonstrated effectiveness of acel-
lular pertussis and influenza vaccination of pregnant women in reducing severe pertus-
sis during early infancy and seasonal influenza illness in the women and their young
infants, respectively. Pertussis and influenza are important causes of pneumonia in
young infants, and pneumonia is a prominent cause of death in early life (3). The first
efficacy trial of a respiratory syncytial virus (RSV) vaccine in pregnant women demon-
strated its potential for preventing the leading cause of severe lower respiratory tract
infection during early infancy, particularly in LMICs (4). The prevention of RSV lower re-
spiratory tract illness in early infancy by immunization in pregnancy may also be aug-
mented through the administration to infants of new-generation monoclonal antibod-
ies that have an extended half-life (5).
In recent years, outbreaks of the H1N1 pandemic influenza, Zika, and Ebola viruses
have severely and uniquely affected pregnant women and their offspring. Ruth Karron
(Johns Hopkins Bloomberg School of Public Health, USA) underlined that pregnant
women must be proactively considered in research agendas and in efforts to deploy
vaccines against emerging infectious diseases; these vaccines have rarely been
designed or developed with pregnant women in mind. For this and other reasons,
pregnant women have in some cases been denied vaccines that would have protected
them and their offspring from severe epidemic threats. This has become particularly
relevant now amid the COVID-19 pandemic. Recommendations to guide the develop-
ment and deployment of appropriate vaccines in these situations did not exist prior to
the recent Ebola outbreak. To address this need, the Pregnancy Research Ethics for
Vaccines, Epidemics, and New Technologies (PREVENT) Working Group was formed.
This is a multidisciplinary, international team of 17 experts specializing in bioethics,
maternal immunization, maternal-fetal medicine, obstetrics, pediatrics, philosophy, pub-
lic health, and vaccine research and policy. After consultation with .100 additional
experts in ethics, public health, vaccine science, maternal and child health, and regula-
tory affairs, the group developed a guidance document that put forth 22 recommenda-
tions across the domains of epidemic preparedness, vaccine research and development,
and vaccine deployment. A key recommendation was the presumption of inclusion, sug-
gesting a change to the traditionally default position, so that pregnant women would be
included in vaccine development and deployment unless their exclusion can be justified
from a scientific and ethical standpoint. The presumption of inclusion reframes decisions
about investments in vaccine research, development, and delivery in ways that are pro-
foundly important for public health and equity, and the principles are similarly applica-
ble to neonates. The PREVENT Working Group recommendations and framework will be
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useful when weighing the potential risks and benefits for pregnant women and their
newborns in the development and deployment of vaccines against current and emerg-
ing epidemic threats, such as COVID-19. Many of the PREVENT recommendations may
also be relevant as the inclusion of pregnant women is more broadly considered in the
context of biomedical research.
PROTECTING NEWBORNS AND INFANTS THROUGHMATERNAL IMMUNIZATION
Data were presented on the various challenges and opportunities related to imple-
mentation of maternal immunization programs in different settings, including LMICs
and high-income countries (HICs). Philipp Lambach (World Health Organization [WHO],
Switzerland) highlighted the efforts by the WHO to support maternal immunization
platforms in LMICs, using tetanus vaccination in pregnancy as a proof of concept of this
approach. The Maternal Immunization and Antenatal Care Situation Analysis (MIACSA) pro-
ject, a collaborative effort between the WHO Departments of Immunization, Vaccines, and
Biologicals (IVB) and Maternal, Newborn, Child, and Adolescent Health (MCA), was under-
taken in 2016 to 2019 (6, 7). MIACSA assessed maternal tetanus vaccine service delivery
strategies and factors associated with effective delivery in low-resource settings, including
collaborations between the immunization program and antenatal care clinic programs,
human resources, finances, information systems, and surveillance. These are key issues
that need to be considered in LMICs to prepare countries for future maternal immuniza-
tion introduction, including vaccines that are required for existing and emerging patho-
gens. Marta Nunes (University of the Witwatersrand, South Africa) reported on how
maternal immunization programs can be effectively implemented in LMICs, using the
example of influenza vaccination campaigns targeted at pregnant women at antenatal
clinics in South Africa. Annette Regan’s (Texas A&M University, USA) findings from the
PREVENT network project emphasized the potential impact of influenza infection on
pregnancy and the newborn (8). Although influenza infection during pregnancy was not
often diagnosed in this international cohort, acute influenza infection during pregnancy
was associated with an increased risk of preterm birth and low birth weight. To highlight
the challenges in vaccine safety surveillance in these settings, Ed Clarke (MRC Unit, The
Gambia) reported on the impact of using the Global Alignment of Immunization Safety
Assessment in Pregnancy (GAIA) Consortium case definitions on the reporting of pre-
term birth in a maternal vaccination trial in The Gambia, comparing levels of variability
in the accuracy of gestational age estimates based on either symphysis-fundal height or
reported last menstrual period data.
Deshayne Fell (University of Ottawa, Canada) described how electronic health care
data, such as insurance claims, health administrative databases, registries, and elec-
tronic health records, are being increasingly used to address important research on
vaccine coverage and safety and the effectiveness of maternal immunization in HICs. In
the United States, studies using the Vaccine Safety Datalink (VSD) have shown the
safety of influenza immunization during pregnancy, with no increases in risks of proxi-
mal adverse events in pregnant individuals or specific adverse obstetric events, such as
hyperemesis, gestational hypertension, gestational diabetes, preeclampsia, or chorio-
amnionitis (9, 10). Similar studies in Norway, Denmark, and Canada have reported no
association between pandemic influenza vaccine and fetal, neonatal, or longer-term
(to age 5 years) pediatric outcomes (11–14). Other studies from the United Kingdom
and United States have confirmed the safety of pertussis immunization during preg-
nancy (15, 16). Meghan Laverty (University of Ottawa, Canada) reported on a popula-
tion-based data linkage study from Canada, identifying no association between expo-
sure to the tetanus, diphtheria, and pertussis (Tdap) vaccine during pregnancy and
early-childhood health outcomes. Annette Regan highlighted the opportunity of data
linkage studies to be used internationally. In the study that she described, a retrospec-
tive cohort of pregnant women in four high-income countries was established using
administrative health data. Hospital records were combined with laboratory testing
data and birth records to identify acute respiratory or febrile illness-related admissions
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during pregnancy and infant outcomes of preterm birth and low birthweight. Such
studies demonstrate the potential perinatal benefits of preventing maternal severe re-
spiratory disease, such as via influenza vaccination (8). Different approaches have suc-
cessfully been used for these data linkage studies, including (i) a distributed data
model in which autonomous software on a centralized secure server accesses site-spe-
cific patient-level data to enable a single combined analysis and (ii) a common data
model in which there is harmonization of protocols to standardize variable definitions
and statistical analysis, with separate site-specific analyses enabling final meta-analysis
of site-specific estimates (17, 18). A number of challenges are encountered using these
approaches, including bias due to differential health care-seeking behaviors, incom-
plete documentation, miscoding by medical records staff, and incomplete linkage or
limited clinical or demographic information.
MULTIDISCIPLINARY APPROACH TO IMPROVE MATERNAL VACCINE UPTAKE
Rolando Ulloa-Gutierrez (Hospital Nacional de Niños, Costa Rica) illustrated how
researchers and governments need to collaborate closely in the field of maternal and
neonatal immunization to ensure that research findings are translated into policy. In
2017, the Pan American Health Organization (PAHO) and WHO published the Maternal
and Neonatal Immunization Field Guide for Latin America and the Caribbean (19), posi-
tioning maternal and neonatal immunization at the highest political level and as a
commitment for member states. Multiple challenges remain, including achieving high
vaccine coverage, protecting dedicated government funding for immunization pro-
grams, and reducing inequality in access to health services. While strong evidence
exists for political authorities to include maternal immunization as a cost-effective
health care priority, catalysts for translating this into policy in Latin America have been
political commitment, endorsement by scientific societies, an established “culture of
vaccination,” widespread access to antenatal care, and context-specific communica-
tions. Facilitators of immunization programs relate to the potential for cost savings,
improved population health, and higher economic productivity. Immunization success
stories, such as the formal elimination of measles, rubella, and congenital rubella syn-
drome in the region, have been a key facilitator to ensure ongoing engagement. When
solid immunization systems are not in place, global events, such as the COVID-19 pan-
demic, can leave many countries highly vulnerable, since the disruption to immuniza-
tion services can lead to a reemergence of vaccine-preventable diseases, such as mea-
sles (20).
Alba Vilajeliu (PAHO, USA) presented data from a study of the current state of
maternal and neonatal immunization policies, strategies, and practices in Latin
America and of the knowledge and perceptions of pregnant women and health work-
ers in this regard, including the importance of integration between immunization and
antenatal care services, similar to the goals of MIACSA. The study suggested an impor-
tant role of health care provider (HCP) recommendations. Penda Johm (MRC Unit, The
Gambia) reported that high levels of acceptance of maternal immunization in The
Gambia are based on previous vaccination experiences, sensitization messages from
trusted HCPs, and monetary incentives. Further data reinforcing the importance of an
HCP recommendation was provided by Neisha Sundaram (London School of Hygiene
and Tropical Medicine [LSHTM], UK); recommendations from doctors were highly val-
ued by pregnant women in Bengaluru, India. However, awareness of and access to vac-
cines other than that for tetanus were limited, highlighting the need for better infor-
mation about maternal vaccines. Karina Top (Canadian Center for Vaccinology,
Canada) presented data from an HIC setting, further examining the information pro-
vided about vaccines given to pregnant women in product monographs and demon-
strating that clear, evidence-based product monographs could support increased vac-
cine uptake in pregnancy (21). Eliz Kilich (LSHTM, UK) provided data from a systematic
review and meta-analysis to examine the factors influencing vaccination decision-mak-
ing among pregnant women, which further reinforced the findings reported from the
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various studies mentioned above; interventions designed to facilitate HCP recommen-
dations are likely to have the strongest impact on maternal vaccine uptake (22). Using
a health beliefs model which included factors such as disease susceptibility, severity,
HCP recommendations, benefit, or utility, disease susceptibility was not a significant
factor for vaccine acceptance in this study. Vaccine safety, however, was a key determi-
nant, and conditions such as autism, narcolepsy, miscarriage, and infertility were noted
concerns.
THEMECHANISTIC UNDERPINNINGS OFMATERNAL ANDNEONATAL IMMUNIZATION
A session on the mechanistic underpinnings of maternal and neonatal immuniza-
tion was organized to (i) illustrate the potential of systems immunology for the under-
standing of the immunobiology of the mother-infant dyad, (ii) provide an update on
the immunobiology of pregnancy and its relevance for vaccine responses, and (iii)
communicate new findings on the rules and mechanisms underlying transplacental
transfer of maternal antibodies. A successful pregnancy requires dynamic changes in
the maternal and fetal immune systems. After birth, the immune systems of the new-
born and young infant develop to meet the challenges of tolerance to commensals
and immunity to infectious pathogens (23). The impacts of these dynamic changes on
the quality of immune responses during pregnancy and soon after birth remain poorly
understood. The emergence of new technologies and computational tools allowing
the integration of large and complex data sets opens new avenues for understanding
the immunobiology of the mother-infant dyad (1).
John Tsang (National Institutes of Health, USA) discussed the potential of systems
biology to discover new components regulating immune responses in pregnancy and
infancy and to develop quantitative models of how these components interact at the
level of the mother-infant dyad. Systems biology approaches have been successfully
applied to the analysis of immune responses to influenza immunization in healthy
adults. Baseline (preimmunization) and vaccine-induced parameters, including blood cell
populations, genes, and serum proteins, are predictors of influenza vaccine responses (24).
Dr. Tsang discussed changes in transcriptional profiles of peripheral blood immune cells
following pertussis immunization of pregnant women and young infants that are candi-
date biomarkers for predicting vaccine responses. Beyond antibodies, correlations were
observed between maternal and infant serum protein profiles that may represent impor-
tant maternal determinants of infant immunity. Single-cell transcriptome analyses identi-
fied key myeloid cell populations driving dynamic changes of immune states during the
first days of life. Together, these data demonstrated the very exciting potential of sys-
tems biology to inform the development of optimized maternal and infant vaccination
strategies.
Transfer of maternal antibodies across the placenta provides rapid protection to the
infant against pathogens to which the mother is immune. Maternal antibodies of dif-
ferent specificities are not transferred equally, but the rules underlying variability in
the transfer process remain poorly understood (25). Madeleine Jennewein (Ragon
Institute, USA) reported on the use of a systems serology approach to investigate the
glycosylation profile and the functional properties of the crystallizable (Fc) fragment of
IgG. Newborn cord blood contained higher concentrations of maternal antibodies pro-
moting NK cell degranulation than maternal blood (26). Data modeling and Ab glyco-
engineering experiments indicated that this preferential transfer of NK cell-activating
Abs was dependent on the expression of galactose by IgG Fc. These data demon-
strated that the transfer of maternal antibodies across the placenta selects specific
structural and functional features that may be critical for optimal neonatal immunity. A
systems serology approach was used by Marcela Pasetti (University of Maryland, USA)
to study the impact of pregnancy on antibody responses to maternal immunization
against influenza; two clearly distinct immune profiles were identified in pregnant and
nonpregnant women in response to seasonal influenza vaccines. Pregnancy had been
associated with increased galactosylation of total IgG, but its impact on vaccine-
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induced antibodies is unknown. Sepideh Dolatshahi (Ragon Institute, USA) described a
systems serology approach to analyze the evolution of maternal antibody features
over the first months of life in preterm versus term newborns, revealing significant dif-
ferences in maternal IgG1 and binding to FcgR. Maternal antibody features of the two
groups then converged during the first months of life, in parallel with their decay, as
observed at the level of serum proteome and immune cell phenotypes (27).
When transferred at high concentrations, maternal antibodies can modulate infant
vaccine responses and commonly decrease their magnitude. However, the impact of
maternal antibodies on the functional properties of vaccine-induced antibodies remains
largely unexplored. Nasamon Wanlapakorn (Chulalonglorn University, Thailand) pre-
sented the results of a randomized trial evaluating the functional properties of antibod-
ies induced by acellular pertussis (aP) versus whole-cell pertussis (wP) vaccines in infants
born to mothers who received the Tdap vaccine during pregnancy (28). The study
showed that in infants, the bactericidal activity of pertussis antibodies was highly de-
pendent on the presence of complement in vitro and that wP vaccination induced
higher serum bactericidal activity than aP vaccination. Although maternal immunization
was associated with lower titers of infant IgG versus pertussis antigens, its impact on se-
rum bactericidal activity was limited, suggesting that high-quality infant antibodies may
be produced even under the cover of maternal antibodies. Studies also suggested that
maternal antibodies have a limited impact on infant T cell responses to vaccines (29).
Marjolein Orije (University of Antwerp, Belgium) reported a study of T cell responses to
pertussis vaccination in preterm and term infants, suggesting that maternal pertussis
vaccination did not influence these cell-mediated responses (29).
The panel discussion of the session emphasized some of the challenges of applying
systems biology to the analysis of vaccine responses in pregnant women and infants,
including uncertainties about optimal sample size and limitations in the number of
samples that can be collected from pregnant women and infants. Systems biology
may inform personalized medicine, but its relevance for global health remains to be
convincingly demonstrated. Systems biology may inform vaccine discovery and devel-
opment to optimize safety and efficacy, but the path to achieve this remains to be
delineated. To provide mechanistic insights, clinical systems biology studies should
integrate upstream and downstream approaches, including animal models and human
in vitromodels, to define mechanisms of action (30).
PROMOTING HEALTHY INFANT LIFE THROUGH OPTIMIZING NEONATAL
IMMUNIZATION
David Goldblatt (University College London, UK) highlighted the global variation in
the etiology of community-acquired neonatal sepsis (31) and suggested that country-
level vaccination strategies should be prioritized according to this epidemiology. Major
challenges for neonatal immunization include perceptions regarding safety and differ-
ences in neonatal immunologic responses from those of older children and adults (32).
Although much of the information about vaccine coverage rates in Africa are available
for children during the first year of life, there is little information about timely adminis-
tration of vaccines given at birth (hepatitis B and Mycobacterium bovis BCG). A publica-
tion from The Gambia (33) revealed that although 93% of 10,851 children did receive
the first dose of the hepatitis B vaccine by the age of 6months, only 1% were vacci-
nated at birth, 5% by day 7, and 58% by day 28. Therefore, interventions to ensure the
successful and timely implementation of neonatal immunization policies are needed.
BCG remains a significant interest because of the potential for nonspecific (heterol-
ogous) immunomodulatory effects resulting in protection against a range of infections,
as postulated for COVID-19 (34–36). However, the duration, magnitude, and impor-
tance of these heterologous effects remain undetermined at this time, and further
studies are ongoing (37). Byron Brook (University of British Columbia [UBC], Canada)
presented a study which characterized the mechanism underlying BCG-induced heter-
ologous immunity against polymicrobial sepsis in neonatal mice and humans (38).
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Neutrophils seemed to be the most important factor; BCG vaccination led to rapid
granulopoiesis and ultimately protection from polymicrobial sepsis within 3 days of
vaccination. An additional challenge is the fact that BCG vaccine production is not
standardized. Kinga Smolen (Boston Children’s Hospital, USA) compared licensed BCG
vaccines, demonstrating marked differences in their contents of live mycobacteria,
which possibly contribute to distinct cytokine and chemokine induction in vitro. It is
not currently known which BCG substrain/formulation offers the best protection.
Paul Heath (St. George’s, University of London, UK) highlighted that preterm infants
have lower-than-normal concentrations of maternal IgG, resulting in increased suscep-
tibility to infection (39), including pertussis, pneumococcus, rotavirus, influenza, and
RSV. This is in part also due to reduced cellular immune responses and lower lympho-
cyte counts (40), as well as lower levels of maternal antibodies. Preterm infants are of-
ten excluded from prelicensure studies of new vaccines, efficacy studies are almost
nonexistent, and immunogenicity studies include small numbers, different schedules,
and different populations and have varied inclusion and exclusion criteria, creating a
challenge in evidence-based decision-making for this population. Preterm infants usu-
ally have lower antibody concentrations after primary vaccination than full-term
infants, but proportions achieving protective concentrations may be equivalent for
vaccines for which correlates of protection have been described (41). Booster doses are
particularly important in these infants. A prospective study in The Netherlands (42)
showed that immunizations were often delayed in preterm infants, being lowest (37%)
in infants ,28weeks of gestational age. Potential adverse events following immuniza-
tion (AEFIs), such as apnea and major cardiorespiratory events, occur more frequently
in preterm infants than in term infants, but overall vaccines are safe in preterm infants,
who should be immunized according to their chronological age and not their cor-
rected gestational age (43). In hospitalized preterm infants, the risk of cardiorespiratory
events after immunization is strongly related to the presence of prematurity-associated
adverse events in the 24 h preceding immunization but not to gestational age, birth
weight, or postnatal age. Maternal immunization is a key mechanism by which these
highly vulnerable infants may be protected, provided that vaccination occurs in the sec-
ond trimester and significant antibody transfer is achieved prior to delivery, although
even then, this would leave the extremely preterm infants vulnerable. For example,
infants born to mothers vaccinated with the Tdap vaccine during pregnancy had signifi-
cantly higher antibody concentrations at 2months for all vaccine antigens than infants
of unvaccinated mothers (44).
Rebecca Ford (Papua New Guinea Institute of Medical Research, Papua New
Guinea) explored approaches to protect infants in Papua New Guinea against pneumo-
coccal disease through different vaccination schedules, including neonatal immuniza-
tion with a pneumococcal conjugate vaccine (PCV), and suggested that there may be a
benefit to a pneumococcal polysaccharide vaccine booster dose in such a strategy.
Results of a randomized controlled trial in The Netherlands on modulation of infant
immune responses after maternal Tdap vaccination were complemented with the
opsonizing capacities of the elicited antibodies in infants. The opsonizing capacity of
antibodies may help us to understand whether this modulation is clinically relevant.
The opsonizing capacity was higher in the offspring of women receiving the Tdap vac-
cine before primary infant vaccination and lower after priming, with similar findings
before and after the second-year-of-life booster. Differences resolved at 2 years of age.
Bahaa Abu Raya (UBC, Canada) reported a meta-analysis of most of the globally
available data on infant immune responses to pertussis, tetanus, diphtheria, and pneu-
mococcal vaccines after maternal Tdap vaccination. Although schedules, epidemiolo-
gies, and vaccines used differed among countries and trials, the modulatory effect of
the Tdap vaccine in pregnancy was observed in most studies for all vaccine antigens.
Lieke van den Elsen (University of Western Australia, Australia) presented data on
the detection of malaria antigens in breastmilk and suggested that such antigens may
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promote immune defenses against Plasmodium falciparum, leading to direct infant im-
munization and reduced malaria risk in breastfed infants.
THE NEXT GENERATIONOF NEONATAL ANDMATERNAL IMMUNIZATION RESEARCH
Studies conducted in Southeast Asia and sub-Saharan Africa (SSA) have highlighted
different contributions of various pathogens to neonatal sepsis, necessitating the de-
velopment of new vaccines for maternal and neonatal immunization (45–47). Stephanie
Schrag (Centers for Disease Control and Prevention, USA) gave a comprehensive over-
view of research needs for the next generation of maternal and neonatal vaccines,
including vaccines against Zika virus (ZIKV), cytomegalovirus (CMV), malaria, and GBS.
Severe congenital microcephaly associated with ZIKV disease in pregnant women
spurred rapid vaccine development during the outbreak in 2015. Despite the apparent
resolution of the epidemic, several agencies are continuing ZIKV vaccine development
to generate a safe vaccine available for future outbreaks (48). CMV causes mild infections
in healthy adults; however, rare but severe complications are observed in 4% to 6% of
congenitally infected infants. Identification of the most suitable target population for
vaccination against CMV is challenging. Vaccine development is advanced, but no vac-
cines against CMV are currently licensed (49). Pregnant women are at increased suscepti-
bility for malaria-related disease, complications, and death, and maternal immunization
should be considered during reviews of phase IV safety data and for future trials of the
PfSPZ malaria vaccine, which is in phase 2 testing (50). A monovalent pertussis vaccine
may be used in maternal and birth dosing regimens, be more affordable than the Tdap
vaccine, and reduce the immune modulation in infants described above (51). GBS is a
leading cause of neonatal sepsis (52). Early-onset disease (,7days) can be prevented by
intrapartum antibiotic prophylaxis (IAP) (53); however, implementation of IAP is not de-
sirable or feasible in many areas due to antimicrobial resistance (AMR) concerns or
resource constraints. Several GBS vaccines are in preclinical and clinical development;
however, challenges exist, as large trials will need to be conducted in areas with
adequate disease burdens, established disease surveillance programs, clinical trial experi-
ence, and the capacity to identify adverse events (54).
Kimberly Center (Pfizer Inc., USA) presented results of a first-in-human study of a
hexavalent GBS conjugate vaccine (GBS6) (NCT03170609). Healthy adults were enrolled
into a randomized, placebo-controlled trial of a single dose of hexavalent GBS vaccine
containing 5, 10, or 20mg capsular polysaccharide of serotypes Ia, Ib, II, III, IV, and V,
with or without aluminum phosphate (AIPO4). Mild-to-moderate local and systemic
reactions were common, but none led to withdrawal from the trial. The vaccine yielded
a robust antibody response, supporting progression to clinical trials in pregnant women.
AMR has been listed as one of the top 10 global threats to human health in 2019,
with deaths related to AMR estimated to be ;700,000 annually and projected to
increase to 10 million by 2050 (55). A recent systematic review (47) reported that AMR
in neonatal sepsis in SSA increased in 2008 to 2018 compared to that in 1980 to 2007.
Staphylococcus aureus contributed to 25% of neonatal sepsis cases in both time peri-
ods. Klebsiella pneumoniae and Escherichia coli were the most commonly identified
Gram-negative bacteria. In the later time period studied, 68% and 27% of bacterial
pathogens were resistant to beta-lactams and aminoglycosides, respectively (3).
Padmini Srikantiah (Bill & Melinda Gates Foundation, USA) described that development
of a K. pneumoniae vaccine for adults is under way and may be considered for vaccina-
tion of pregnant women to reduce neonatal sepsis in the future (56). A recombinant
monoclonal antibody to staphylococcal protein A (SpA) has shown promising results in
a mouse model and may be considered at birth (57).
Louis Fries (Novavax, Inc., USA) shared the results of a maternal immunization trial
with a respiratory syncytial virus F protein vaccine (4). The vaccine was found to be
safe, with no significant negative vaccine effects on pregnancy, delivery, or infant birth
outcomes or adverse events. The overall vaccine efficacy was 39% against medically
significant RSV lower respiratory tract infection, with increased efficacy for more-severe
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disease endpoints. Vaccine efficacy was higher in LMICs than in HICs, which may have
been due to higher severe disease incidence, earlier immunization, better alignment
with RSV season, and/or more persistent breastfeeding in LMICs. This vaccine has the
potential to significantly impact clinical pneumonia in infants, especially in LMICs.
Shigella is an important cause of diarrhea in children; however, there is no licensed
vaccine available yet. Esther Ndungo (University of Maryland School of Medicine, USA)
presented the results of a 2-year longitudinal study of 100 mothers and infants con-
ducted in Malawi to determine the repertoire, functional capacity, and maternal-infant
transfer efficiency of antibodies against Shigella, identifying differences between levels
of transfer of all Shigella-specific IgGs and functional antibodies; further understanding
of this would be critical for any Shigella vaccine.
COVID-19 AND THE MATERNAL-INFANT DYAD
During the current COVID-19 pandemic, concerns have been raised about the possi-
bility of vertical or perinatal transmission of SARS-CoV-2 and the effect of the infection
on the pregnant woman, the fetus, or the infant. Disease severity and complications of
COVID-19 appear to be relatively low during pregnancy, although multiple interna-
tional studies are ongoing (58). Multiple recent reports suggest an increased risk of in-
tensive care unit admission, invasive ventilation, and possibly mortality in pregnant indi-
viduals compared with that for nonpregnant individuals of reproductive age (59–61).
Considerations for inclusion of pregnant women in the evaluation of COVID-19 vaccines
are already under way.
The most common clinical manifestations of COVID-19 in pregnancy have been
reported as fever (40%) and cough (39%). Pregnant women are less likely to report
fever and myalgia than nonpregnant women of reproductive age. Increased maternal
age, high body mass index, chronic hypertension, and prior diabetes have been linked
with severe COVID-19 in pregnancy. Regarding obstetric complications, several publi-
cations suggest the possibility of adverse obstetric outcomes in women with COVID-
19, including Caesarean section, premature birth, low birth weight, and adverse preg-
nancy events (62, 63). However, rates vary by the location, type, and size of studies.
Multiple registries are in place to continue to monitor this as the pandemic progresses,
and carefully controlled analyses will be required to appropriately determine any modi-
fied risk due to COVID-19 in pregnancy. SARS-CoV-2 has not been detected in human
milk in multiple studies, except for one case in Germany (64).
Vertical transmission of SARS-CoV-2 to the infant is a potential concern, for which
initial case series did not show substantial evidence (65–67). Some recent reports sug-
gest the probability of vertical transmission (68, 69). A case definition and potential
mechanisms of vertical transmission have been suggested (69–71). A recent systematic
review of neonatal COVID-19 infections identified that 71% were confirmed/probably
acquired postnatally, 3.3% were acquired intrapartum (with an additional 14% prob-
ably/possibly acquired intrapartum), and 5.7% were confirmed congenital cases (with a
further 6.5% probably/possible congenital) (68). Variations in testing strategies around
the world have made it challenging to confirm accurately the true vertical transmission
rates.
CONCLUDING REMARKS
Maternal and neonatal immunization is an effective key strategy in reducing death
and significant morbidity from infectious diseases globally. While significant progress
has been made in the implementation of maternal immunization programs in various
regions and settings worldwide, much remains to be done. The integration of maternal
immunization and antenatal care programs is critical, and local solutions which can
adapt to different specific needs and a variety of settings are required. Our increased
understanding of the mechanistic underpinnings of maternal and neonatal immuniza-
tion will enable further vaccine development to be based on a bedrock of scientific evi-
dence. Ongoing surveillance of known and emerging infectious diseases affecting
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women during pregnancy and infants in early life is required to ensure that the devel-
opment and implementation of safe new vaccines remain relevant to the prevention
of severe disease in these potentially highly susceptible populations. At a time of
global challenges to health care systems worldwide due to the SARS-CoV-2 pandemic,
ensuring the continuation of vaccination programs for pregnant women and newborns
must remain an international priority.
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